|
⚲
|
| Keyboard |
| Bioimpact Capital LLC
✚
|
|
|---|---|
| CRD # | 309865 |
| SEC # | 801-119133 |
| CIK # | 0001796461, 0001687078, 0000168707 |
| AUM | |
| Employees | 50 (62% Investors, 0% Brokers) |
| Fees | |
| Minimum | |
| Phone | 617-425-9200 |
| Address | 399 Boylston Street Boston, MA 02116 |
| Source | [IAPD] [EDGAR] [Website] [Twitter] [LinkedIn] |
| Total AUM ($B) |
|---|
| Fees and Compensation — Form ADV Part 2A (11/17/2022) [Brochure] |
|---|
Item 5. Fees and Compensation The Adviser, or its affiliates, generally receive Advisory Fees and either Performance Allocations or Carried Interest (each as defined below) or similar performance-based remuneration from a Fund. A Fund, and/or its portfolio companies may also make other payments to the Adviser or its affiliates for services provided to the portfolio companies which, in certain circumstances, may reduce the Advisory Fees payable to the Adviser. Additionally, consistent with the Organizational Documents of a Fund, the Fund typically bears certain out-of-pocket expenses incurred by the Adviser in connection with the services provided to the Fund and/or the portfolio companies. Further details about certain common fees and expenses are set forth below. Advisory Fees As compensation for investment supervisory services rendered to the Funds, the Adviser receives from each such Fund an advisory fee (each, an “Advisory Fee”) typically calculated based on committed capital or net asset value, with respect to such Fund. Advisory Fees may be reduced during the life of a Fund. The precise amount of, and the manner and calculation of, the Advisory Fees for each Fund are established by the Adviser and are set forth in such Fund’s Organizational Documents. The Advisory Fees and other fees and distributions described herein are generally subject to modification, waiver, or reduction by the Adviser in its sole discretion, both voluntarily and on a negotiated basis with selected investors via side letter and other arrangements, which may not be disclosed to other investors in the same Fund. The fee structures described herein may be modified from time to time. Fees may differ from one Fund to another, as well as among investors in the same Fund. The Advisory Fees paid by certain Funds will generally be reduced by (1) the amount of fees paid by such Fund to persons acting as a placement agent in connection with the offer and sale of interests in such Fund to certain potential investors, (2) the fees incurred by the Adviser in connection with the organization of such Fund that exceed a limit specified in such Fund’s Organizational Documents, and/or (3) certain other fees (see Other Fees and Expense Reimbursement below) received by the Adviser or its affiliates. The amount and manner of such reduction, if any, is set forth in the Organizational Documents of the applicable Fund. Advisory Fees vary Fund by Fund and are either payable quarterly or monthly in advance. There are also legacy Advisory Fee and performance fee structures that are generally no longer available to new investors. Certain investors in the Funds that are employees, business associates, and other “friends and family” of the Adviser, its affiliates or their personnel, including any related entity established by any of the foregoing, such as trusts, charitable programs, endowments or related programs, family investment vehicles and other estate planning vehicles (collectively, “Adviser Investors”) will not typically pay Advisory Fees in connection with their investment in a Fund. Furthermore, Adviser Investors do not generally bear any expenses incurred in making an investment and, as a result, such expenses are generally borne by the Funds. Adviser Investors will only bear those expenses specifically allocated solely to an Adviser Investor vehicle (for instance, formation expenses, administrative fees, tax preparation fees, state filing fees and similar fees). The Adviser may from time to time in the future establish certain investment vehicles through which certain Adviser Investors, other “friends of the firm,” or other persons may invest alongside one or more Funds in one or more investment opportunities. Such co-investment vehicles generally will not pay Advisory Fees or Carried Interest. The Adviser or an affiliated General Partner deducts Advisory Fees and Performance Allocations/Carried Interest directly from Fund assets and does not bill investors in the Funds. Upon termination, prepaid Advisory Fees are processed in accordance with the terms of the applicable Advisory Agreement. Performance Allocations The affiliated General Partner of certain Funds receives performance-based compensation generally equal to 20% of the excess net profit over net losses for each year for each investor, subject to a high watermark (the “Performance Allocation”). The Performance Allocation is generally made to the respective General Partner at the end of each year or sooner upon withdrawals by investors. Please see Item 6 below regarding Performance Allocation. Carried Interest Payments With respect to certain Funds, a portion of the profits of each such Fund is distributed to its General Partner, if any, as “carried interest” (the “Carried Interest”), generally equal to 20%. Please see Item 6 below regarding Carried Interest. Other Fees and Expense Reimbursement Other Fees In addition to the Advisory Fees, Performance Allocation, and Carried Interest, the Adviser and its affiliates receive a variety of other cash, equity, and other non-cash fees relating to the investment activities of certain Funds, their portfolio companies, and prospective portfolio companies, including operational fees, and/or other similar fees received from portfolio companies and/or prospective portfolio companies (collectively with the other fees described in this section, “Other Fees”). The amount and timing of such fees received by the Adviser or its affiliates are generally specified in the agreement or other documentation governing the applicable transaction. In addition, the Adviser’s personnel, from time to time, receive stock of a portfolio company due to the service of such personnel on the board of such portfolio company or as compensation for other services provided to such portfolio company. In such event, the recipient will generally act ... |
| Account Minimums and Types of Clients — Form ADV Part 2A (11/17/2022) [Brochure] |
|---|
Item 7. Types of Clients The Adviser currently provides investment supervisory services to the Funds. Investment advice is provided directly to the Funds (subject to the direction and control of the General Partner or board of directors of each such Fund, as applicable) and not individually to investors in such Fund. Interests in the Funds are offered pursuant to applicable exemptions from registration under the Securities Act and the 1940 Act. Investors in the Funds are generally “qualified purchasers” as defined in the 1940 Act, and may include, among others, public pension plans, corporate pension plans, endowments, private pension plans, foundations, insurance companies, fund-of-funds, family offices, Operations Support Providers, other institutional investors, and high-net worth individuals. The Adviser does not have a minimum size for a Fund, but minimum investment commitments may be established for investors in the Funds. The General Partner or board of directors of each Fund may, in its sole discretion, permit investments below the minimum amounts set forth in the Organizational Documents of such Fund. |
| CIK | Period |
|---|---|
| 0001796461 0001687078 0000168707 |
| Sector | Form 13F Holdings | Value ($M) | |
|---|---|---|---|
| DBV Technologies Sa | 108.9 | ||
| Cullinan Oncology Inc | 108.7 | ||
| Liquidia Corp | 53.0 | ||
| Alumis Inc | 52.6 | ||
| Edgewise Therapeutics Inc | 52.3 | ||
| Revolution Medicines Inc | 49.3 | ||
| Agios Pharmaceuticals Inc | 44.2 | ||
| Corcept Therapeutics Inc | 39.7 | ||
| Trevi Therapeutics Inc | 39.4 | ||
| Magenta Therapeutics Inc | 35.6 | ||
| Xenon Pharmaceuticals Inc | 34.2 | ||
| Helix Acquisition Corp | 33.8 | ||
| Desert Gateway Inc | 33.7 | ||
| Evommune Inc | 33.5 | ||
| Cytokinetics Inc | 33.0 | ||
| Syndax Pharmaceuticals Inc | 31.3 | ||
| Context Therapeutics Inc | 28.0 | ||
| Tocagen Inc | 25.9 | ||
| Marika Inc | 25.7 | ||
| Dyne Therapeutics Inc | 25.5 | ||
| Stoke Therapeutics Inc | 25.0 | ||
| Corvus Pharmaceuticals Inc | 24.5 | ||
| Relay Therapeutics Inc | 23.5 | ||
| Tarsus Pharmaceuticals Inc | 23.1 | ||
| Oric Pharmaceuticals Inc | 22.9 | ||
| Uniqure NV | 22.4 | ||
| Monte Rosa Therapeutics Inc | 19.4 | ||
| Natera Inc | 18.6 | ||
| Eliem Therapeutics Inc | 17.8 | ||
| Prev | Page 1 | Next | |||
| AUM Breakdown | Accounts | AUM ($B) |
|---|---|---|
| By Client Type | ||
| (a) Individuals (other than high net worth individuals) | 0 | 0.0 |
| (b) Individuals (high net worth individuals) | 0 | 0.0 |
| (c) Banking or thrift institutions | 0 | 0.0 |
| (d) Investment companies | 0 | 0.0 |
| (e) Business development companies | 0 | 0.0 |
| (f) Pooled investment vehicles | 9 | 2.0 |
| (g) Pension and profit sharing plans | 0 | 0.0 |
| (h) Charitable organizations | 0 | 0.0 |
| (i) State or municipal government entities | 0 | 0.0 |
| (j) Other investment advisers | 0 | 0.0 |
| (k) Insurance companies | 0 | 0.0 |
| (l) Sovereign wealth funds and foreign official institutions | 0 | 0.0 |
| (m) Corporations or other businesses not listed above | 0 | 0.0 |
| (n) Other | 0 | 0.0 |
| Total | 9 | 2.0 |
| By Discretionary | ||
| Discretionary | 9 | 2.0 |
| Non-Discretionary | 0 | 0.0 |
| Total | 9 | 2.0 |
| By Non-United States Persons | ||
| Non-United States Persons | 1.9 | |
| United States Persons | 0.1 | |
| Total | 9 | 2.0 |
| EDGAR Form | CIK | 2011 - 2026 |
|---|---|---|
| 13F-HR | [0001687078] | |
| 3 | [0001687078] | |
| 4 | [0001687078] | |
| SC 13D | [0001687078] | |
| SC 13G | [0001687078] | |
| 13F-HR | [0001796461] | |
| SC 13G | [0001796461] |
| Firm Profile (Form ADV) | |
|---|---|
| Serves | Institutional |
| Fund Types | Hedge Fund |
| Insider Transaction (Form 3/4/5) | Date | Action | Shares | Price | Value ($) |
|---|---|---|---|---|---|
|
Werewolf Therapeutics Inc HOWL
Common Stock
|
2025-12-04 | Sell | 83,230 | $0.97 | 80,733 |
|
Werewolf Therapeutics Inc HOWL
Common Stock
|
2025-12-03 | Sell | 57,225 | $0.87 | 49,786 |
|
Werewolf Therapeutics Inc HOWL
Common Stock
|
2025-12-02 | Sell | 59,277 | $0.89 | 52,757 |
|
Werewolf Therapeutics Inc HOWL
Common Stock
|
2025-12-01 | Sell | 60,917 | $0.94 | 57,262 |
|
Werewolf Therapeutics Inc HOWL
Common Stock
|
2025-11-28 | Sell | 20,277 | $0.99 | 20,074 |
|
Werewolf Therapeutics Inc HOWL
Common Stock
|
2025-11-26 | Sell | 60,733 | $0.98 | 59,518 |
|
Werewolf Therapeutics Inc HOWL
Common Stock
|
2025-11-25 | Sell | 42,533 | $0.92 | 39,130 |
|
Werewolf Therapeutics Inc HOWL
Common Stock
|
2025-11-24 | Sell | 88,802 | $0.98 | 87,026 |
|
Werewolf Therapeutics Inc HOWL
Common Stock
|
2025-11-21 | Sell | 64,331 | $0.83 | 53,395 |
|
Werewolf Therapeutics Inc HOWL
Common Stock
|
2025-11-20 | Sell | 41,152 | $0.89 | 36,625 |
|
Werewolf Therapeutics Inc HOWL
Common Stock
|
2025-11-19 | Sell | 66,324 | $0.94 | 62,345 |
|
Werewolf Therapeutics Inc HOWL
Common Stock
|
2025-11-18 | Sell | 52,627 | $0.93 | 48,943 |
|
Werewolf Therapeutics Inc HOWL
Common Stock
|
2025-11-17 | Sell | 57,061 | $0.95 | 54,208 |
|
Werewolf Therapeutics Inc HOWL
Common Stock
|
2025-11-14 | Sell | 61,640 | $0.93 | 57,325 |
|
Werewolf Therapeutics Inc HOWL
Common Stock
|
2025-11-13 | Sell | 90,951 | $0.98 | 89,132 |
|
Werewolf Therapeutics Inc HOWL
Common Stock
|
2025-11-12 | Sell | 40,669 | $1.09 | 44,329 |
|
Werewolf Therapeutics Inc HOWL
Common Stock
|
2025-11-11 | Sell | 55,810 | $1.14 | 63,623 |
|
Werewolf Therapeutics Inc HOWL
Common Stock
|
2025-11-10 | Sell | 48,570 | $1.18 | 57,313 |
|
Werewolf Therapeutics Inc HOWL
Common Stock
|
2025-11-07 | Sell | 68,480 | $1.11 | 76,013 |
|
Werewolf Therapeutics Inc HOWL
Common Stock
|
2025-11-06 | Sell | 54,452 | $1.21 | 65,887 |
| showing 20 of 200 most recent transactions | |||||